Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Asset Writedowns and Impairment (2023)

Historic Asset Writedowns and Impairment for Cyclerion Therapeutics (CYCN) over the last 1 years, with Q3 2023 value amounting to $3.3 million.

  • Cyclerion Therapeutics' Asset Writedowns and Impairment changed N/A to $3.3 million in Q3 2023 from the same period last year, while for Dec 2024 it was $3.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $3.3 million for FY2023, which is N/A changed from last year.
  • Cyclerion Therapeutics' Asset Writedowns and Impairment amounted to $3.3 million in Q3 2023.
  • Cyclerion Therapeutics' 5-year Asset Writedowns and Impairment high stood at $3.3 million for Q3 2023, and its period low was $3.3 million during Q3 2023.